2 May 2024 in Terapevticheskii arkhiv
In September 2023, the European Association for the Study of the Liver (EASL) updated the disease nomenclature for non-alcoholic (metabolically associated) fatty liver disease. The goals of the revision were to increase awareness among health care professionals, civil society and patients about the disease, its course, treatment and outcomes; combating stigma; focusing on the initial etiological factor, including the main (cardiometabolic) risk of disease progression; improved diagnosis based on disease biomarkers; positive impact on the potency to search for new drugs; the ability to provide personalized medical care. The terms “non-alcoholic” and “fatty” were considered stigmatizing, and therefore, it was proposed to use the term steatotic liver disease (SLD) as the name of this nosology. The terms non-alcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) have been replaced by the term metabolic dysfunction-associated steatotic liver disease (MASLD). In the case of being combined with an alcohol factor, a diagnosis in which metabolic dysfunction is combined with alcoholic liver disease is referred to as MetALD. The fundamental principle in the diagnosis of MASLD is the presence of at least one of the cardiometabolic risk factors. Alcohol consumption interacts with cardiometabolic risk factors and increases the risk of SLD decompensation. The term nonalcoholic steatohepatitis (NASH), according to the new nomenclature, has been replaced by the term metabolic dysfunction-associated steatohepatitis (MASH). The adoption of the new nomenclature should help to increase awareness about the disease, its course and outcomes, as well as improve the quality of diagnosis and treatment.
23 April 2024 in Russian Journal of Pain
Objective. To conduct a systematic review of data on efficacy and safety of metamizole sodium (MS) for pain syndrome in adults and children. Material and methods. A systematic review was conducted. At the first stage, we reviewed available databases regarding efficacy and safety of MS for pain syndrome in adults and children compared to other analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Analysis included 38 randomized clinical trials and 5435 patients (children over 3 years old and adults). Results. MS significantly reduces pain syndrome compared to placebo within 30-60 min after administration. VAS scores decrease by more than 50% in 70-100% of cases. Effectiveness of MS is not inferior to paracetamol, acetylsalicylic acid, diclofenac, ibuprofen, ketorolac, ketoprofen and parecoxib. Effectiveness of different forms of MS is similar. At the same time, parenteral MS provides longer pain control compared to oral forms. MS in postoperative period reduces the need for reserve analgesics, including opioids. Unlike other NSAIDs, MS does not lead to gastric erosions, peptic ulcers or gastrointestinal bleeding. There is no effect on blood clotting. MS has good tolerability and safety comparable to the most popular NSAIDs. The risk of adverse events is lower compared to opioid analgesics. No serious adverse events were registered. Conclusion. MS is effective and safe in adolescents over 15 years old and adults with pain syndrome.